Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Type:
Grant
Filed:
October 5, 2011
Date of Patent:
July 16, 2013
Assignees:
Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SAS
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Type:
Grant
Filed:
October 5, 2011
Date of Patent:
June 18, 2013
Assignees:
Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SAS
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Type:
Grant
Filed:
July 11, 2011
Date of Patent:
June 18, 2013
Assignees:
Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SAS
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Type:
Grant
Filed:
July 11, 2011
Date of Patent:
June 18, 2013
Assignees:
Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SAS